Scientific Programme

Monday, March 19, 2018

09.00                      Registration Opens

11.00                       Welcome Address

11.10 – 11.40           Impact of translational research on current immunotherapy trial programs
Ulrich Keilholz, Berlin, Germany

11.40 – 13.10          Opening – Plenary Symposium 1: Overcoming Immune Escape

Tumor/Immune Cell Metabolism

Current understanding of resistance to immunotherapy
Samir Khleif, Augusta, GA, USA

Which cells respond to anti PD1/L1 therapy

13.10 – 14.00        Lunch

14.00 – 15.00        Satellite Symposium

15.00 – 15.30        Coffee Break

15.30 – 18.00        Plenary Symposium 2: Emerging concepts / novel agents

STING activation sequenced with immune checkpoint modulators overcomes immune tolerance
Leisha Emens, Baltimore, MD, USA

IDO inhibition in combination with checkpoint inhibition

Combination of anti-LAG 3 antibodies with other checkpoint inhibitors
Paolo Ascierto, Naples, Italy

TLR and checkpoint inhibitor mediated immune modulation in tumor draining lymph nodes
Tanja de Gruijl, Amsterdam, Netherlands

Platelets, GARP and Cancer Immunotherapy
Zihai Li, Charleston, SC, USA

18.20                       Welcome Reception and Poster Viewing

Tuesday, March 20, 2018

08.30 – 09.30        Combination of T cell engagers with checkpoint inhibitors in immune-
excluded tumors

09.30-10.30            Plenary Symposium 3: Innate Immunity

Reprogramming macrophages for tumour immunity
Michele de Palma, Lausanne, Switzerland

Harnessing NK cell memory for cancer immunotherapy
Jasper van den Boorn, Bonn, Germany

PD-1 expression on innate lymphoid cells
Shoba Amarnath, Newcastle Upon Tyne, United Kingdom

10.30 – 11.00          Coffee Break

11.00 – 13.00         Plenary Symposium 4: Anti-cancer vaccines

Tumor antigen-specific T cell epitopes – identification and clinical application
Stefan Eichmueller, Heidelberg, Germany

Neoantigen vaccination

Development of a DC vaccines and combinations
Lisa Butterfield, Pittsburgh, PA, USA

Combination therapy with anti-cancer vaccines and checkpoint Inhibitors
Lei Zheng, Baltimore, MD

12.50 – 14.00          Lunch

14.00 – 15.00          Satellite Symposium

15.00 – 15.45           Lifetime Achievement Award
CAR T cells in haematological malignancies: focused on the cure
Carl June, Philadelphia, PA, USA

15.45 – 16.15           Coffee Break

16.15 – 18.00          Plenary Symposium 5: Cell therapy

Adoptive T cell therapy of glioblastoma
Bryan Choi, Boston, MA, USA

Arming T cells with C-X-C Motive Receptor 6 as a universal approach for tumor directed T cell
Sebastian Kobold, Munich, Germany

18.00                        Poster Viewing

19.30                        ITOC5 Conference Dinner

Wednesday, March 21, 2018

08.30 – 10.00        Plenary Symposium 6: Monitoring of Immune response

Detection of tumour-infiltration immune cells by PET
Hidde Ploegh, Boston, MA, USA

Tissue biomarkers of response to Immunotherapy
Julien Adam, Villejuif, France

Tumor mutational burden as biomarker in NSCLC
Solange Peters, Lausanne, Switzerland

PD-L1 as biomarker in thoracic malignancies

10.00 – 10.30         Coffee Break

10.30 – 12.30         Plenary Symposium 7: Clinical Breakthrough with Immunotherapy
Joint Session with ESMO

Adjuvant Therapy of Melanoma

Lung Cancer
Luis Paz-Ares, Madrid, Spain

Renal cell carcinoma

 12.30 – 12.45         Closing Remarks

 12.45 – 13.45          Lunch


ITOC5 frames:

ITOC5 frames_Page_1